Citations (75)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (11)
Riccardo Lacchini & Jose E Tanus-Santos. (2014) Pharmacogenetics of Erectile Dysfunction: Navigating into Uncharted Waters. Pharmacogenomics 15:11, pages 1519-1538.
Read now
Read now
Karen Rowland Yeo, Masoud Jamei & Amin Rostami-Hodjegan. (2013) Predicting drug–drug interactions: application of physiologically based pharmacokinetic models under a systems biology approach. Expert Review of Clinical Pharmacology 6:2, pages 143-157.
Read now
Read now
Guillaume Baneyx, Yumi Fukushima & Neil Parrott. (2012) Use Of Physiologically Based Pharmacokinetic Modeling For Assessment Of Drug–Drug Interactions. Future Medicinal Chemistry 4:5, pages 681-693.
Read now
Read now
Hannah M Jones, Maurice Dickins, Kuresh Youdim, James R Gosset, Neil J Attkins, Tanya L Hay, Ian K Gurrell, Y Raj Logan, Peter J Bungay, Barry C Jones & Iain B Gardner. (2012) Application of PBPK modelling in drug discovery and development at Pfizer. Xenobiotica 42:1, pages 94-106.
Read now
Read now
C. R. Gibson, A. Bergman, P. Lu, F. Kesisoglou, W. S. Denney & E. Mulrooney. (2009) Prediction of Phase I single-dose pharmacokinetics using recombinant cytochromes P450 and physiologically based modelling. Xenobiotica 39:9, pages 637-648.
Read now
Read now
Pascal Espié, Dominique Tytgat, Maria-Laura Sargentini-Maier, Italo Poggesi & Jean-Baptiste Watelet. (2009) Physiologically based pharmacokinetics (PBPK). Drug Metabolism Reviews 41:3, pages 391-407.
Read now
Read now
Masoud Jamei, Steve Marciniak, Kairui Feng, Adrian Barnett, Geoffrey Tucker & Amin Rostami-Hodjegan. (2009) The Simcyp® Population-based ADME Simulator. Expert Opinion on Drug Metabolism & Toxicology 5:2, pages 211-223.
Read now
Read now
Olavi Pelkonen, Jaime Kapitulnik, Ursula Gundert-Remy, AlanR. Boobis & Armel Stockis. (2008) Local Kinetics and Dynamics of Xenobiotics. Critical Reviews in Toxicology 38:8, pages 697-720.
Read now
Read now
T. Lavé, N. Parrott, H. P. Grimm, A. Fleury & M. Reddy. (2007) Challenges and opportunities with modelling and simulation in drug discovery and drug development. Xenobiotica 37:10-11, pages 1295-1310.
Read now
Read now
M. R. Shiran, N. J. Proctor, E. M. Howgate, K. Rowland-Yeo, G. T. Tucker & A. Rostami-Hodjegan. (2006) Prediction of metabolic drug clearance in humans: extrapolation allometric scaling. Xenobiotica 36:7, pages 567-580.
Read now
Read now
H. Yamazaki, A. Okayama, N. Imai, F. P. Guengerich & M. Shimizu. (2006) Inter-individual variation of cytochrome P4502J2 expression and catalytic activities in liver microsomes from Japanese and Caucasian populations. Xenobiotica 36:12, pages 1201-1209.
Read now
Read now
Articles from other publishers (64)
Hiroaki Iijima, Hidetoshi Shimizu, Kazumi Mori-Anai, Atsuhiro Kawaguchi, Yoji Mochida, Toshimasa Yamauchi & Takashi Kadowaki. (2023) Evaluation of Age-Related Changes in Teneligliptin Pharmacokinetics in Japanese and European Descent Subjects Using a Physiologically Based Pharmacokinetic Model. Diabetes Therapy 15:4, pages 763-777.
Crossref
Crossref
Estefania Traver, Laura Rodríguez‐Pascau, Uwe Meya, Guillem Pina, Silvia Pascual, Sonia Poli, David Eckland, Jeroen van de Wetering, Alice Ke, Andreas Lindauer, Marc Martinell & Pilar Pizcueta. (2024)
Clinical pharmacokinetics of leriglitazone and a translational approach using
PBPK
modeling to guide the selection of the starting dose in children
. CPT: Pharmacometrics & Systems Pharmacology.
Crossref
Crossref
Udoamaka Ezuruike, Liam Curry, Oliver Hatley & Iain Gardner. (2024) Exploring the impact of ethnicity on drug pharmacokinetics using PBPK models: A case study with lansoprazole in Japanese subjects. British Journal of Clinical Pharmacology.
Crossref
Crossref
Maxime Le Merdy, Ke Xu Szeto, Jeremy Perrier, Michael B. Bolger & Viera Lukacova. (2024) PBPK Modeling Approach to Predict the Behavior of Drugs Cleared by Metabolism in Pregnant Subjects and Fetuses. Pharmaceutics 16:1, pages 96.
Crossref
Crossref
Paulo Paixão, Luís Gouveia, José Augusto Guimarães Morais & Nuno Silva. 2024. Concepts and Models for Drug Permeability Studies. Concepts and Models for Drug Permeability Studies
641
663
.
Mariam A. Ahmed, Janelle Burnham, Gaurav Dwivedi & Bilal AbuAsal. (2023) Achieving big with small: quantitative clinical pharmacology tools for drug development in pediatric rare diseases. Journal of Pharmacokinetics and Pharmacodynamics 50:6, pages 429-444.
Crossref
Crossref
Trevor N. Johnson, Khaled Abduljalil, Xian Pan & Chie Emoto. (2023) Development and Verification of a Japanese Pediatric Physiologically Based Pharmacokinetic Model with Emphasis on Drugs Eliminated by Cytochrome P450 or Renal Excretion. The Journal of Clinical Pharmacology 63:10, pages 1156-1168.
Crossref
Crossref
Eko Setiawan, Menino Osbert Cotta, Jason A. Roberts & Mohd Hafiz Abdul-Aziz. (2023) A Systematic Review on Antimicrobial Pharmacokinetic Differences between Asian and Non-Asian Adult Populations. Antibiotics 12:5, pages 803.
Crossref
Crossref
Ben G. Small, Trevor N. Johnson & Karen Rowland Yeo. (2022) Another Step Toward Qualification of Pediatric Physiologically Based Pharmacokinetic Models to Facilitate Inclusivity and Diversity in Pediatric Clinical Studies. Clinical Pharmacology & Therapeutics 113:3, pages 735-745.
Crossref
Crossref
Karthik Venkatakrishnan, Neeraj Gupta, Patrick F. Smith, Tiffany Lin, Neil Lineberry, Tatiana Ishida, Lin Wang & Mark Rogge. (2022) Asia‐Inclusive Clinical Research and Development Enabled by Translational Science and Quantitative Clinical Pharmacology: Toward a Culture That Challenges the Status Quo. Clinical Pharmacology & Therapeutics 113:2, pages 298-309.
Crossref
Crossref
Jeffry Adiwidjaja, Annette S. Gross, Alan V. Boddy & Andrew J. McLachlan. (2021) Physiologically‐based pharmacokinetic model predictions of inter‐ethnic differences in imatinib pharmacokinetics and dosing regimens. British Journal of Clinical Pharmacology 88:4, pages 1735-1750.
Crossref
Crossref
Takeshi Akiyoshi, Marika Uchiyama, Rino Inada, Ayuko Imaoka & Hisakazu Ohtani. (2022) Analysis of inhibition kinetics of three beverage ingredients, bergamottin, dihydroxybergamottin and resveratrol, on CYP2C9 activity. Drug Metabolism and Pharmacokinetics 42, pages 100429.
Crossref
Crossref
Akiko Watanabe, Tomoko Ishizuka, Makiko Yamada, Yoshiyuki Igawa, Takako Shimizu & Hitoshi Ishizuka. (2021) Physiologically based pharmacokinetic modelling to predict the clinical effect of CYP3A inhibitors/inducers on esaxerenone pharmacokinetics in healthy subjects and subjects with hepatic impairment. European Journal of Clinical Pharmacology 78:1, pages 65-73.
Crossref
Crossref
Kentaro Ohta, Nobuko Matsushima, Hiromi Tanii, Herta Crauwels, Toshiyuki Kudo & Kiyomi Ito. (2021) Pharmacokinetics and safety of rilpivirine in healthy Japanese subjects and exploration of ethnic sensitivity of rilpivirine pharmacokinetics with physiologically based pharmacokinetic model approach. Drug Metabolism and Pharmacokinetics 41, pages 100422.
Crossref
Crossref
Sheila Annie Peters. 2021. Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulations. Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulations
567
577
.
Trevor N. Johnson & Alice B. Ke. (2021) Physiologically Based Pharmacokinetic Modeling and Allometric Scaling in Pediatric Drug Development: Where Do We Draw the Line?. The Journal of Clinical Pharmacology 61:S1.
Crossref
Crossref
Takafumi Kato, Tsuyoshi Mikkaichi, Yasushi Yoshigae, Noriko Okudaira, Takako Shimizu, Takashi Izumi, Shuichi Ando & Yoshiaki Matsumoto. (2021) Quantitative analysis of an impact of P-glycoprotein on edoxaban's disposition using a human physiologically based pharmacokinetic (PBPK) model. International Journal of Pharmaceutics 597, pages 120349.
Crossref
Crossref
Chandra Prakash, Bin Fan, Alice Ke, Kha Le & Hua Yang. (2020) Physiologically based pharmacokinetic modeling and simulation to predict drug–drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia. Cancer Chemotherapy and Pharmacology 86:5, pages 619-632.
Crossref
Crossref
Kosuke Doki, Keisuke Kuga, Kazutaka Aonuma, Masaki Ieda & Masato Homma. (2020) Utilizing physiologically based pharmacokinetic modeling to predict theoretically conceivable extreme elevation of serum flecainide concentration in an anuric hemodialysis patient with cirrhosis. European Journal of Clinical Pharmacology 76:6, pages 821-831.
Crossref
Crossref
Jia Ning, Ivonne M. C. M. Rietjens & Marije Strikwold. (2019) Integrating physiologically based kinetic (PBK) and Monte Carlo modelling to predict inter-individual and inter-ethnic variation in bioactivation and liver toxicity of lasiocarpine. Archives of Toxicology 93:10, pages 2943-2960.
Crossref
Crossref
Yuki Matsumoto, Tamara Cabalu, Punam Sandhu, Georgy Hartmann, Takashi Iwasa, Hiroyuki Yoshitsugu, Christopher Gibson & Naoto Uemura. (2018) Application of Physiologically Based Pharmacokinetic Modeling to Predict Pharmacokinetics in Healthy Japanese Subjects. Clinical Pharmacology & Therapeutics 105:4, pages 1018-1030.
Crossref
Crossref
Qiang Zhang, Jin Li, Alistair Middleton, Sudin Bhattacharya & Rory B. Conolly. (2018) Bridging the Data Gap From in vitro Toxicity Testing to Chemical Safety Assessment Through Computational Modeling. Frontiers in Public Health 6.
Crossref
Crossref
Jiachang Gong, Lisa Iacono, Ramaswamy A. Iyer, William G. Humphreys & Ming Zheng. (2018) Physiologically‐based pharmacokinetic modelling of a CYP2C19 substrate, BMS‐823778, utilizing pharmacogenetic data. British Journal of Clinical Pharmacology 84:6, pages 1335-1345.
Crossref
Crossref
Sijie Lu, R. A. Nand, J. S. Yang, Gang Chen & A. S. Gross. (2017) Pharmacokinetics of CYP2C9, CYP2C19, and CYP2D6 substrates in healthy Chinese and European subjects. European Journal of Clinical Pharmacology 74:3, pages 285-296.
Crossref
Crossref
Holly M. Mortensen, John Chamberlin, Bonnie Joubert, Michelle Angrish, Nisha Sipes, Janice S. Lee & Susan Y. Euling. (2018) Leveraging human genetic and adverse outcome pathway (AOP) data to inform susceptibility in human health risk assessment. Mammalian Genome 29:1-2, pages 190-204.
Crossref
Crossref
Caroline L. Ring, Robert G. Pearce, R. Woodrow Setzer, Barbara A. Wetmore & John F. Wambaugh. (2017) Identifying populations sensitive to environmental chemicals by simulating toxicokinetic variability. Environment International 106, pages 105-118.
Crossref
Crossref
Wangda Zhou, Helen Humphries, Sibylle Neuhoff, Iain Gardner, Eric Masson, Nidal Al‐Huniti & Diansong Zhou. (2017) Development of a physiologically based pharmacokinetic model to predict the effects of flavin‐containing monooxygenase 3 (FMO3) polymorphisms on itopride exposure. Biopharmaceutics & Drug Disposition 38:6, pages 389-393.
Crossref
Crossref
Jan Snoeys, Maria Beumont, Mario Monshouwer & Sivi Ouwerkerk-Mahadevan. (2016) Elucidating the Plasma and Liver Pharmacokinetics of Simeprevir in Special Populations Using Physiologically Based Pharmacokinetic Modelling. Clinical Pharmacokinetics 56:7, pages 781-792.
Crossref
Crossref
Chirag Patel, Chetan Rathi & Karthik Venkatakrishnan. (2016) Should Race‐Genotype Interactions Be Considered in the Global Development of CYP2C19 Substrates? A Proposed Framework Using Physiologically Based Pharmacokinetic Modeling. The Journal of Clinical Pharmacology 57:4, pages 417-421.
Crossref
Crossref
Daniel H. Hovelson, Zhengyu Xue, Matthew Zawistowski, Margaret G. Ehm, Elizabeth C. Harris, Sophie L. Stocker, Annette S. Gross, In-Jin Jang, Ichiro Ieiri, Jong-Eun Lee, Lon R. Cardon, Stephanie L. Chissoe, Gonçalo Abecasis & Matthew R. Nelson. (2017) Characterization of ADME gene variation in 21 populations by exome sequencing. Pharmacogenetics and Genomics 27:3, pages 89-100.
Crossref
Crossref
Sheng Feng, Jun Shi, Neil Parrott, Pei Hu, Cornelia Weber, Meret Martin-Facklam, Tomohisa Saito & Richard Peck. (2015) Combining ‘Bottom-Up’ and ‘Top-Down’ Methods to Assess Ethnic Difference in Clearance: Bitopertin as an Example. Clinical Pharmacokinetics 55:7, pages 823-832.
Crossref
Crossref
K Venkatakrishnan, C Burgess, N Gupta, A Suri, T Takubo, X Zhou, D DeMuria, M Lehnert, K Takeyama, S Singhvi & A Milton. (2016) Toward Optimum Benefit‐Risk and Reduced Access Lag For Cancer Drugs in Asia: A Global Development Framework Guided by Clinical Pharmacology Principles. Clinical and Translational Science 9:1, pages 9-22.
Crossref
Crossref
Janne T. Backman, Anne M. Filppula, Mikko Niemi & Pertti J. Neuvonen. (2015) Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions. Pharmacological Reviews 68:1, pages 168-241.
Crossref
Crossref
Paulo Paixão, Luís Gouveia, José Augusto Guimarães Morais & Nuno Silva. 2016. Concepts and Models for Drug Permeability Studies. Concepts and Models for Drug Permeability Studies
357
371
.
Haifeng Zhang, Na Gao, Xin Tian, Tingting Liu, Yan Fang, Jun Zhou, Qiang Wen, Binbin Xu, Bing Qi, Jie Gao, Hongmeng Li, Linjing Jia & Hailing Qiao. (2015) Content and activity of human liver microsomal protein and prediction of individual hepatic clearance in vivo. Scientific Reports 5:1.
Crossref
Crossref
Ni-Ni Lin, Jia Chen, Bin Xu, Xia Wei, Lei Guo & Jian-Wei Xie. (2015) The roles of carboxylesterase and CYP isozymes on the in vitro metabolism of T-2 toxin. Military Medical Research 2:1.
Crossref
Crossref
Aki T. Heikkinen, Floriane Lignet, Paul Cutler & Neil Parrott. (2015) The role of quantitative ADME proteomics to support construction of physiologically based pharmacokinetic models for use in small molecule drug development. PROTEOMICS – Clinical Applications 9:7-8, pages 732-744.
Crossref
Crossref
Sheng Feng, Yumi Cleary, Neil Parrott, Pei Hu, Cornelia Weber, Yongqing Wang, Ophelia Q. P. Yin & Jun Shi. (2015) Evaluating a physiologically based pharmacokinetic model for prediction of omeprazole clearance and assessing ethnic sensitivity in CYP2C19 metabolic pathway. European Journal of Clinical Pharmacology 71:5, pages 617-624.
Crossref
Crossref
Khaled Abduljalil, Theresa Cain, Helen Humphries & Amin Rostami-Hodjegan. (2014) Deciding on Success Criteria for Predictability of Pharmacokinetic Parameters from In Vitro Studies: An Analysis Based on In Vivo Observations. Drug Metabolism and Disposition 42:9, pages 1478-1484.
Crossref
Crossref
Hannah M. Jones & Neil Parrott. 2014. Predictive ADMET. Predictive ADMET
167
188
.
Heidi J. Einolf & Imad Hanna. 2014. Predictive ADMET. Predictive ADMET
353
396
.
Li Di, Bo Feng, Theunis C. Goosen, Yurong Lai, Stefanus J. Steyn, Manthena V. Varma & R. Scott Obach. (2013) A Perspective on the Prediction of Drug Pharmacokinetics and Disposition in Drug Research and Development. Drug Metabolism and Disposition 41:12, pages 1975-1993.
Crossref
Crossref
Zoe E. Barter, Geoffrey T. Tucker & Karen Rowland-Yeo. (2013) Differences in Cytochrome P450-Mediated Pharmacokinetics Between Chinese and Caucasian Populations Predicted by Mechanistic Physiologically Based Pharmacokinetic Modelling. Clinical Pharmacokinetics 52:12, pages 1085-1100.
Crossref
Crossref
Neil Parrott, Dominik Hainzl, Daniela Alberati, Carsten Hofmann, Richard Robson, Bruno Boutouyrie & Meret Martin-Facklam. (2013) Physiologically Based Pharmacokinetic Modelling to Predict Single- and Multiple-Dose Human Pharmacokinetics of Bitopertin. Clinical Pharmacokinetics 52:8, pages 673-683.
Crossref
Crossref
C Emoto, T Fukuda, S Cox, U Christians & AA Vinks. (2013) Development of a Physiologically‐Based Pharmacokinetic Model for Sirolimus: Predicting Bioavailability Based on Intestinal CYP3A Content. CPT: Pharmacometrics & Systems Pharmacology 2:7, pages 1-9.
Crossref
Crossref
Sravanthi Cheeti, Nageshwar R. Budha, Sharmila Rajan, Mark J. Dresser & Jin Y. Jin. (2013) A physiologically based pharmacokinetic (PBPK) approach to evaluate pharmacokinetics in patients with cancer. Biopharmaceutics & Drug Disposition 34:3, pages 141-154.
Crossref
Crossref
A Rostami-Hodjegan. (2012) Physiologically Based Pharmacokinetics Joined With In Vitro–In Vivo Extrapolation of ADME: A Marriage Under the Arch of Systems Pharmacology. Clinical Pharmacology & Therapeutics 92:1, pages 50-61.
Crossref
Crossref
Alexander V. LyubimovFrédéric Y. Bois & Masoud Jamei. 2011. Encyclopedia of Drug Metabolism and Interactions. Encyclopedia of Drug Metabolism and Interactions
1
27
.
Christopher L. Shaffer, Renato J. Scialis, Haojing Rong & R. Scott Obach. (2012) Using Simcyp to project human oral pharmacokinetic variability in early drug research to mitigate mechanism‐based adverse events. Biopharmaceutics & Drug Disposition 33:2, pages 72-84.
Crossref
Crossref
Sheila Annie Peters. 2012. Physiologically‐Based Pharmacokinetic (PBPK) Modeling and Simulations. Physiologically‐Based Pharmacokinetic (PBPK) Modeling and Simulations
407
421
.
Alexander V. LyubimovHan‐Joo Maeng, Edwin C. Y. Chow, Jianghong Fan & K. Sandy Pang. 2011. Encyclopedia of Drug Metabolism and Interactions. Encyclopedia of Drug Metabolism and Interactions
1
48
.
James B. Knaak, Curtis C. Dary, Xiaofei Zhang, Robert W. Gerlach, R. Tornero-Velez, Daniel T. Chang, Rocky Goldsmith & Jerry N. Blancato. 2012. Reviews of Environmental Contamination and Toxicology. Reviews of Environmental Contamination and Toxicology
1
114
.
Hisakazu Ohtani, Zoe Barter, Tsuyoshi Minematsu, Masatoshi Makuuchi, Yasufumi Sawada & Amin Rostami‐Hodjegan. (2011) Bottom‐up modeling and simulation of tacrolimus clearance: prospective investigation of blood cell distribution, sex and CYP3A5 expression as covariates and assessment of study power. Biopharmaceutics & Drug Disposition 32:9, pages 498-506.
Crossref
Crossref
Jiansong Yang. 2011. Systems Biology in Drug Discovery and Development. Systems Biology in Drug Discovery and Development
59
92
.
Hirotaka Kawakami, Sumio Ohtsuki, Junichi Kamiie, Takashi Suzuki, Takaaki Abe & Tetsuya Terasaki. (2011) Simultaneous Absolute Quantification of 11 Cytochrome P450 Isoforms in Human Liver Microsomes by Liquid Chromatography Tandem Mass Spectrometry with In Silico Target Peptide Selection. Journal of Pharmaceutical Sciences 100:1, pages 341-352.
Crossref
Crossref
K. Sandy Pang & Matthew R. Durk. (2010) Physiologically-based pharmacokinetic modeling for absorption, transport, metabolism and excretion. Journal of Pharmacokinetics and Pharmacodynamics 37:6, pages 591-615.
Crossref
Crossref
Trevor N. Johnson, Koen Boussery, Karen Rowland-Yeo, Geoffrey T. Tucker & Amin Rostami-Hodjegan. (2010) A Semi-Mechanistic Model to Predict the Effects of Liver Cirrhosis on Drug Clearance. Clinical Pharmacokinetics 49:3, pages 189-206.
Crossref
Crossref
Shigeki Bamba, Tomoyuki Tsujikawa, Osamu Inatomi, Tamio Nakahara, Yusuke Koizumi, Yasuharu Saitoh, Masaya Sasaki, Yoshihide Fujiyama & Akira Andoh. (2010) Factors affecting the efficacy of cyclosporin A therapy for refractory ulcerative colitis. Journal of Gastroenterology and Hepatology 25:3, pages 494-498.
Crossref
Crossref
R. Scott Obach. 2009. Enzyme Inhibition in Drug Discovery and Development. Enzyme Inhibition in Drug Discovery and Development
241
264
.
Claudia Leoni, Franca M. Buratti & Emanuela Testai. (2008) The participation of human hepatic P450 isoforms, flavin-containing monooxygenases and aldehyde oxidase in the biotransformation of the insecticide fenthion. Toxicology and Applied Pharmacology 233:2, pages 343-352.
Crossref
Crossref
Franca M. Buratti & Emanuela Testai. (2007) Evidences for CYP3A4 autoactivation in the desulfuration of dimethoate by the human liver. Toxicology 241:1-2, pages 33-46.
Crossref
Crossref
Gemma L. Dickinson & Amin Rostami‐Hodjegan. 2007. Biosimulation in Drug Development. Biosimulation in Drug Development
425
446
.
Amin Rostami-Hodjegan & Geoffrey T. Tucker. (2007) Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nature Reviews Drug Discovery 6:2, pages 140-148.
Crossref
Crossref
Trevor N Johnson, Amin Rostami-Hodjegan & Geoffrey T Tucker. (2006) Prediction of the Clearance of Eleven Drugs and Associated Variability in Neonates, Infants and Children. Clinical Pharmacokinetics 45:9, pages 931-956.
Crossref
Crossref